In his latest post to our firm’s Norfolk Injuryboard blog, my colleague Rick Shapiro argues that federal lawmakers and the U.S. Food and Drug Administration must hold makers of generic medications and brand-name drugmakers to the same standards for warning patients about dangerous drug side effects. Rick’s concern over the unequal treatment of the pharmaceutical manufacturers was triggered by the June 23, 2011, U.S. Supreme Court decision in Pliva Inc. et al. v. Mensing, which some analysts have read as a free pass from failure-to-warn liability for generic drug companies.
EJL